Seres Therapeutics, Inc. and Nestlé Health Science announced that VOWST (fecal microbiota spores, live-brpk) is now commercially available for patients. VOWST,formerly called SER-109, is the first and only U.S. Food and Drug Administration (FDA)-approved orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). VOWST is not indicated for the treatment of CDI.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9199 USD | -0.49% | -10.69% | -34.29% |
09/05 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
09/05 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.29% | 14Cr | |
+9.42% | 11TCr | |
+11.84% | 10TCr | |
-14.15% | 2.24TCr | |
-1.05% | 2.23TCr | |
-5.29% | 1.91TCr | |
-38.29% | 1.8TCr | |
-4.16% | 1.79TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.25TCr |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™